CDC’s Assay for Global Surveillance of Drug-resistant HIV-1 Was Commercialized

FLC logo

Researchers at the Centers for Disease Control and Prevention (CDC) developed a low-cost technology to rapidly detect HIV-1 drug resistance (HIVDR) in plasma and dried blood spot (DBS) samples with 95.8% genotyping sensitivity. CDC’s partners at Life Technologies Corporation (“LifeTech”) have licensed, further developed, and incorporated the technology into a commercialized product. Life Tech’s HIV-1 Genotyping Kit provides a cost-effective assay, scalable workflow, easy-to read sequencing results, and robust test performance.

SARS-CoV-2 Virus Specimen and Material Sharing

FLC logo

The Centers for Disease Control and Prevention (CDC) and the National Institute for Allergy and Infectious Diseases (NIAID) have been rewarded for their partnership from the 2021 Federal Laboratory Consortium (FLC) awards. The CDC and NIAID had already developed a new approach to sharing samples during a Public Health Emergency of International Concern (PHEIC) during the Zika pandemic, which enabled them to respond quickly and efficiently to access and share samples of SARS-CoV-2 early in the outbreak.

Patrick McCue

Dr. McCue joined OTT in June 2009. Prior to joining OTT, Dr. McCue was a technology transfer fellow at the National Cancer Institute (NCI)’s Technology Transfer Center. Dr. McCue completed research fellowships at the NCI-Frederick, at the National Center for Complementary and Alternative Medicine (NCCAM), and at the Genome Research Facility of the National Aeronautics and Space Administration (NASA). Registered to practice before the U.S. Patent and Trademark Office, Dr.

Subscribe to CDC